219 related articles for article (PubMed ID: 18006843)
1. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
Halder J; Lin YG; Merritt WM; Spannuth WA; Nick AM; Honda T; Kamat AA; Han LY; Kim TJ; Lu C; Tari AM; Bornmann W; Fernandez A; Lopez-Berestein G; Sood AK
Cancer Res; 2007 Nov; 67(22):10976-83. PubMed ID: 18006843
[TBL] [Abstract][Full Text] [Related]
2. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Halder J; Kamat AA; Landen CN; Han LY; Lutgendorf SK; Lin YG; Merritt WM; Jennings NB; Chavez-Reyes A; Coleman RL; Gershenson DM; Schmandt R; Cole SW; Lopez-Berestein G; Sood AK
Clin Cancer Res; 2006 Aug; 12(16):4916-24. PubMed ID: 16914580
[TBL] [Abstract][Full Text] [Related]
3. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.
Halder J; Landen CN; Lutgendorf SK; Li Y; Jennings NB; Fan D; Nelkin GM; Schmandt R; Schaller MD; Sood AK
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8829-36. PubMed ID: 16361572
[TBL] [Abstract][Full Text] [Related]
4. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
Golubovskaya VM; Virnig C; Cance WG
Mol Carcinog; 2008 Mar; 47(3):222-34. PubMed ID: 17849451
[TBL] [Abstract][Full Text] [Related]
5. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y
Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
Fukami S; Tomioka D; Murakami Y; Honda T; Hatakeyama S
BMC Res Notes; 2019 Jun; 12(1):347. PubMed ID: 31215459
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.
Kurio N; Shimo T; Fukazawa T; Okui T; Hassan NM; Honami T; Horikiri Y; Hatakeyama S; Takaoka M; Naomoto Y; Sasaki A
Oral Oncol; 2012 Nov; 48(11):1159-70. PubMed ID: 22766511
[TBL] [Abstract][Full Text] [Related]
8. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
[TBL] [Abstract][Full Text] [Related]
10. TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.
Schultze A; Decker S; Otten J; Horst AK; Vohwinkel G; Schuch G; Bokemeyer C; Loges S; Fiedler W
Invest New Drugs; 2010 Dec; 28(6):825-33. PubMed ID: 19784551
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
12. TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma.
Moritake H; Saito Y; Sawa D; Sameshima N; Yamada A; Kinoshita M; Kamimura S; Konomoto T; Nunoi H
Cancer Med; 2019 Dec; 8(18):7809-7821. PubMed ID: 31692287
[TBL] [Abstract][Full Text] [Related]
13. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN
Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439
[TBL] [Abstract][Full Text] [Related]
14. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Liu TJ; LaFortune T; Honda T; Ohmori O; Hatakeyama S; Meyer T; Jackson D; de Groot J; Yung WK
Mol Cancer Ther; 2007 Apr; 6(4):1357-67. PubMed ID: 17431114
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer.
Hao HF; Takaoka M; Bao XH; Wang ZG; Tomono Y; Sakurama K; Ohara T; Fukazawa T; Yamatsuji T; Fujiwara T; Naomoto Y
Biochem Biophys Res Commun; 2012 Jul; 423(4):744-9. PubMed ID: 22705303
[TBL] [Abstract][Full Text] [Related]
17. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
Merritt WM; Lin YG; Spannuth WA; Fletcher MS; Kamat AA; Han LY; Landen CN; Jennings N; De Geest K; Langley RR; Villares G; Sanguino A; Lutgendorf SK; Lopez-Berestein G; Bar-Eli MM; Sood AK
J Natl Cancer Inst; 2008 Mar; 100(5):359-72. PubMed ID: 18314475
[TBL] [Abstract][Full Text] [Related]
18. 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
Hehlgans S; Lange I; Eke I; Cordes N
Radiother Oncol; 2009 Sep; 92(3):371-8. PubMed ID: 19729215
[TBL] [Abstract][Full Text] [Related]
19. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Takaoka M; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2008 Dec; 20(6):1473-7. PubMed ID: 19020730
[TBL] [Abstract][Full Text] [Related]
20. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.
Lee SJ; Ghosh SC; Han HD; Stone RL; Bottsford-Miller J; Shen DY; Auzenne EJ; Lopez-Araujo A; Lu C; Nishimura M; Pecot CV; Zand B; Thanapprapasr D; Jennings NB; Kang Y; Huang J; Hu W; Klostergaard J; Sood AK
Clin Cancer Res; 2012 Aug; 18(15):4114-21. PubMed ID: 22693353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
